SCHEMBL406782

SCHEMBL406782

Nc1cc(F)c(Cl)cc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.50
CYP3A4 P08684 1/20 0.46
IDO1 P14902 1/20 0.46
NFE2L2 Q16236 1/20 0.44
ALDH1A1 P00352 5/20 0.44
POLB P06746 3/20 0.44
HPGD P15428 2/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 3/20 0.44
KMT2A Q03164 2/20 0.44
GFER P55789 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
PKM P14618 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1096218 0.92 KEAP1 (0.50) KEAP1CYP3A4IDO1NFE2L2ALDH1A1
SCHEMBL2315912 0.84 SLC9A1 (0.44) IDO1ALDH1A1HPGDGAAKMT2A
SCHEMBL3544203 0.84 KEAP1 (0.46) KEAP1CYP3A4NFE2L2ALDH1A1POLB
SCHEMBL3031603 0.83 CYP3A4 (0.52) KEAP1CYP3A4IDO1ALDH1A1POLB
SCHEMBL31586627 0.83 KEAP1 (0.55) KEAP1NFE2L2ALDH1A1POLBHPGD
SCHEMBL222733 0.83 KEAP1 (0.57) KEAP1CYP3A4IDO1NFE2L2ALDH1A1
SCHEMBL364382 0.81 KEAP1 (0.48) KEAP1NFE2L2ALDH1A1POLBHPGD
SCHEMBL363365 0.81 KEAP1 (0.48) KEAP1NFE2L2ALDH1A1POLBHPGD
SCHEMBL29488312 0.81 KEAP1 (0.48) KEAP1NFE2L2ALDH1A1POLBHPGD
SCHEMBL18669166 0.81 SLC9A1 (0.58) KEAP1CYP3A4IDO1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4211119-B1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 EP disclosed
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-03-10 US disclosed
US-12473291-B2 Benzodiazepine compound, preparation method therefor, and use thereof in medicine WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) 2025-11-18 US disclosed
US-12275715-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2025-04-15 US disclosed
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 US disclosed
WO-2024261327-A1 2-(HETEROARYL-THIO)-1-(HETEROARYL)ETHANONE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 WO disclosed
WO-2024261329-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 WO disclosed
US-12103921-B2 Chemical compounds PFIZER INC. (US) 2024-10-01 US disclosed
US-12091399-B2 Phenyltetrazole derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-09-17 US disclosed
US-7582627-B2 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase WARNER-LAMBERT COMPANY (US) 2009-09-01 US disclosed
US-7582627-B2 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase WARNER-LAMBERT COMPANY (US) 2009-09-01 US disclosed
EP-1255739-B1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2008-06-11 EP disclosed
EP-1255739-B1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2008-06-11 EP disclosed
US-20060287308-A1 3-Aminoquinazolin-2,4-dione antibacterial agents ZOETIS WLC LLC 2006-12-21 US disclosed
US-7094780-B1 3-aminoquinazolin-2,4-dione antibacterial agents WARNER LAMBERT COMPANY LLC (US) 2006-08-22 US disclosed
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ZOETIS WLC LLC 2006-08-17 US disclosed
CN-1425008-A 3-aminoquinazolin-2, 4-dione antibacterial agents WARNER LAMBERT CO (US) 2003-06-18 CN disclosed
EP-1255739-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2002-11-13 EP disclosed
WO-2001053273-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183762-A1 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS ABL1, NQO2, CBR3 KEAP1 533/4885CYP3A4 1188/4885IDO1 801/4885
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof LRRK2, PARK7, CLK2 KEAP1 472/4885CYP3A4 4424/4885IDO1 3651/4885
US-12275715-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH2 KEAP1 589/4885CYP3A4 2681/4885IDO1 194/4885
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT KEAP1 1343/4885CYP3A4 4294/4885IDO1 2876/4885
US-12103921-B2 Chemical compounds HBZ, HBB, HBS1L KEAP1 484/4885CYP3A4 34/4885IDO1 2827/4885
US-20060287308-A1 3-Aminoquinazolin-2,4-dione antibacterial agents ABL1, NQO2, AAAS KEAP1 478/4885CYP3A4 1134/4885IDO1 830/4885
US-12091399-B2 Phenyltetrazole derivatives as plasma kallikrein inhibitors KLKB1, SERPINE1, SERPINB1 KEAP1 1495/4885CYP3A4 255/4885IDO1 987/4885
US-12473291-B2 Benzodiazepine compound, preparation method therefor, and use thereof in medicine GABRA1, GABRA4, GABRR1 KEAP1 1767/4885CYP3A4 57/4885IDO1 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.